• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

三特异性杀伤细胞衔接器 CD16xIL15xCD33 可强力诱导 NK 细胞活化，并对肿瘤性肥大细胞发挥细胞毒性作用。

Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells.

机构信息

Division of Hematology, Oncology, and Transplantation, Department of Medicine, and.

Department of Therapeutic Radiology-Radiation Oncology, University of Minnesota, Minneapolis, MN.

出版信息

Blood Adv. 2018 Jul 10;2(13):1580-1584. doi: 10.1182/bloodadvances.2018018176.

DOI:10.1182/bloodadvances.2018018176
PMID:29980573
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6039654/
Abstract

NK cell natural cytotoxicity and antibody-dependent cellular cytotoxicity of patients with systemic mastocytosis are normal. Trispecific killer engagers (161533 TriKE) target NK cells from normal donors and systemic mastocytosis patients to kill mast cells.

摘要

系统性肥大细胞增多症患者的 NK 细胞自然细胞毒性和抗体依赖性细胞细胞毒性正常。三特异性杀伤嵌合分子（161533 TriKE）以正常供体和系统性肥大细胞增多症患者的 NK 细胞为靶点，以杀死肥大细胞。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58df/6039654/81d278b61fd9/advances018176absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58df/6039654/81d278b61fd9/advances018176absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58df/6039654/81d278b61fd9/advances018176absf1.jpg

相似文献

1
Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells.三特异性杀伤细胞衔接器 CD16xIL15xCD33 可强力诱导 NK 细胞活化，并对肿瘤性肥大细胞发挥细胞毒性作用。
Blood Adv. 2018 Jul 10;2(13):1580-1584. doi: 10.1182/bloodadvances.2018018176.
2
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.白细胞介素15三特异性杀伤细胞衔接器（TriKE）使自然杀伤细胞对CD33+靶点具有特异性，同时还能诱导其持久性、体内扩增及功能增强。
Clin Cancer Res. 2016 Jul 15;22(14):3440-50. doi: 10.1158/1078-0432.CCR-15-2710. Epub 2016 Feb 4.
3
161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS.161533 TriKE 可刺激 NK 细胞功能，克服 MDS 中的髓系来源抑制细胞。
Blood Adv. 2018 Jun 26;2(12):1459-1469. doi: 10.1182/bloodadvances.2017012369.
4
CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.CD16xCD33 双特异性杀伤细胞接合器（BiKE）作为儿科 AML 和双表型 ALL 患者潜在的免疫治疗药物。
Cancer Immunol Immunother. 2021 Dec;70(12):3701-3708. doi: 10.1007/s00262-021-03008-0. Epub 2021 Aug 16.
5
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.CD16xCD33 双特异性杀伤细胞接合器 (BiKE) 激活 NK 细胞对抗原发性 MDS 和 MDSC CD33+靶标。
Blood. 2014 May 8;123(19):3016-26. doi: 10.1182/blood-2013-10-533398. Epub 2014 Mar 20.
6
A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells.一种针对 CLEC12A 的三特异性杀伤剂分子可有效诱导 NK 细胞杀伤 AML 细胞。
Leukemia. 2021 Jun;35(6):1586-1596. doi: 10.1038/s41375-020-01065-5. Epub 2020 Oct 23.
7
Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.用 CD16x33 双特异性杀伤细胞接合器和 ADAM17 抑制物在体外靶向急性髓系白血病的自然杀伤细胞。
Clin Cancer Res. 2013 Jul 15;19(14):3844-55. doi: 10.1158/1078-0432.CCR-13-0505. Epub 2013 May 20.
8
Licensed human natural killer cells aid dendritic cell maturation via TNFSF14/LIGHT.经许可的人类自然杀伤细胞通过TNFSF14/LIGHT促进树突状细胞成熟。
Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):E5688-96. doi: 10.1073/pnas.1411072112. Epub 2014 Dec 15.
9
Therapeutic applications: natural killer cells in the clinic.治疗应用：临床中的自然杀伤细胞
Hematology Am Soc Hematol Educ Program. 2013;2013:247-53. doi: 10.1182/asheducation-2013.1.247.
10
Retroviral gene transfer into primary human NK cells activated by IL-2 and K562 feeder cells expressing membrane-bound IL-21.逆转录病毒基因转导入由白细胞介素-2和表达膜结合型白细胞介素-21的K562饲养细胞激活的原代人自然杀伤细胞。
J Immunol Methods. 2017 Nov;450:90-94. doi: 10.1016/j.jim.2017.08.003. Epub 2017 Aug 10.

引用本文的文献

1
Killing the killers: Natural killer cell therapy targeting glioma stem cells in high-grade glioma.杀死杀手：针对高级别胶质瘤中胶质瘤干细胞的自然杀伤细胞疗法。
Mol Ther. 2025 Jun 4;33(6):2462-2478. doi: 10.1016/j.ymthe.2025.02.043. Epub 2025 Mar 3.
2
Bispecific and multispecific antibodies in oncology: opportunities and challenges.双特异性和多特异性抗体在肿瘤学中的应用：机遇与挑战。
Nat Rev Clin Oncol. 2024 Jul;21(7):539-560. doi: 10.1038/s41571-024-00905-y. Epub 2024 May 31.
3
Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.

本文引用的文献

1
GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity.糖原合成酶激酶3抑制促进自然杀伤细胞成熟并增强其抗肿瘤活性。
Cancer Res. 2017 Oct 15;77(20):5664-5675. doi: 10.1158/0008-5472.CAN-17-0799. Epub 2017 Aug 8.
2
Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia.在与急性髓系白血病相关的系统性肥大细胞增多症中，异基因自然杀伤细胞可根除成髓细胞，但不能根除肿瘤性肥大细胞。
Am J Hematol. 2017 May;92(5):E66-E68. doi: 10.1002/ajh.24673. Epub 2017 Feb 24.
3
Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice.
针对晚期肥大细胞增多症的抗体和细胞治疗：既定和新的概念。
Int J Mol Sci. 2023 Oct 12;24(20):15125. doi: 10.3390/ijms242015125.
4
Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer.NK 细胞衔接双特异性抗体治疗癌症的原则和临床现状。
Hum Vaccin Immunother. 2023 Aug;19(2):2256904. doi: 10.1080/21645515.2023.2256904. Epub 2023 Sep 29.
5
Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy.自然杀伤细胞接合剂（NKCEs）：癌症免疫治疗的新前沿。
Front Immunol. 2023 Aug 9;14:1207276. doi: 10.3389/fimmu.2023.1207276. eCollection 2023.
6
Crosstalk of Mast Cells and Natural Killer Cells with Neurons in Chemotherapy-Induced Peripheral Neuropathy.肥大细胞与自然杀伤细胞同神经元在化疗诱导的周围神经病中的串扰。
Int J Mol Sci. 2023 Aug 8;24(16):12543. doi: 10.3390/ijms241612543.
7
Engineering cytokines for cancer immunotherapy: a systematic review.工程细胞因子用于癌症免疫治疗：系统评价。
Front Immunol. 2023 Jul 6;14:1218082. doi: 10.3389/fimmu.2023.1218082. eCollection 2023.
8
Umbilical cord blood derived cellular therapy: advances in clinical development.脐带血来源的细胞疗法：临床开发进展
Front Oncol. 2023 May 18;13:1167266. doi: 10.3389/fonc.2023.1167266. eCollection 2023.
9
Mapping the interplay between NK cells and HIV: therapeutic implications.描绘 NK 细胞与 HIV 之间的相互作用：治疗意义。
J Leukoc Biol. 2023 Feb 1;113(2):109-138. doi: 10.1093/jleuko/qiac007.
10
Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry.推动癌症免疫治疗的下一步发展：从基于抗体的双特异性药物到多特异性药物，生物共轭化学的作用不断演变。
RSC Chem Biol. 2021 Oct 22;3(2):140-169. doi: 10.1039/d1cb00082a. eCollection 2022 Feb 9.
高级系统性肥大细胞增多症：从分子和遗传学进展到临床实践。
Haematologica. 2016 Oct;101(10):1133-1143. doi: 10.3324/haematol.2016.146563.
4
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.中剂量伊马替尼治疗晚期系统性肥大细胞增多症的疗效和安全性。
N Engl J Med. 2016 Jun 30;374(26):2530-41. doi: 10.1056/NEJMoa1513098.
5
Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis.晚期系统性肥大细胞增多症异基因造血细胞移植的共识意见
Biol Blood Marrow Transplant. 2016 Aug;22(8):1348-1356. doi: 10.1016/j.bbmt.2016.04.018. Epub 2016 Apr 27.
6
Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia.吉妥珠单抗奥唑米星对一名难治性肥大细胞白血病患者的完全缓解。
Leukemia. 2016 Aug;30(8):1753-6. doi: 10.1038/leu.2016.30. Epub 2016 Feb 15.
7
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.白细胞介素15三特异性杀伤细胞衔接器（TriKE）使自然杀伤细胞对CD33+靶点具有特异性，同时还能诱导其持久性、体内扩增及功能增强。
Clin Cancer Res. 2016 Jul 15;22(14):3440-50. doi: 10.1158/1078-0432.CCR-15-2710. Epub 2016 Feb 4.
8
Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.晚期系统性肥大细胞增多症的造血干细胞移植
J Clin Oncol. 2014 Oct 10;32(29):3264-74. doi: 10.1200/JCO.2014.55.2018. Epub 2014 Aug 25.
9
A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection.一种表达功能性 IgE 受体的新型人类肥大细胞系通过 KIT D816V 转染转化为致瘤性生长。
Blood. 2014 Jul 3;124(1):111-20. doi: 10.1182/blood-2013-10-534685. Epub 2014 Mar 27.
10
Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells.针对上皮细胞黏附分子（EpCAM）和CD16的异二聚体双特异性单链可变片段抗体可诱导对人癌细胞产生有效的抗体依赖性细胞毒性。
Cancer Biother Radiopharm. 2013 May;28(4):274-82. doi: 10.1089/cbr.2012.1329. Epub 2013 Apr 23.